![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, March 13, 2010 2:04:46 PM
Same story on both links.
http://www.emailwire.com/release/36013-AP-Pharma-Inc-Public-NASDAQAPPA-PDUFA-Date-of-March-18th-Rapidly-Approaches-for-APF530.html
http://www.thefirstreporter.com/press-releases/a-p-pharma-inc-public-nasdaqappa-pdufa-date-of-march-18th-rapidly-approaches-for-apf530/#axzz0i5HPVVPb
A.P. Pharma, Inc., (Public, NASDAQ:APPA) PDUFA Date of March 18th Rapidly Approaches for APF530
Many factors influence the FDA’s decision when considering a drug candidate for approval. In this case, there are some factors that weigh heavily in favor of A.P. Pharma, Inc., (Public, NASDAQ:APPA).
(EMAILWIRE.COM, March 13, 2010 )NY,NY TapeBeat.Com, the news and research portal for the serious investor is proud to present information regarding A.P. Pharma, Inc., (Public, NASDAQ:APPA) a specialty pharmaceutical company based in Redwood City, California. Its current pipeline utilizes a group of polymeric compounds dubbed Biochronomer as its drug delivery mechanism with a number of advantages over current delivery means. Probably the most important advantage of the Biochronomer system is that the actives (drugs) can be incorporated into a drug matrix by simple physical mixing means that allow injectable gels, microspheres, coatings and strands to be created depending on the necessary application. Each of these different forms is capable of controlling site and speed of the active ingredient delivery without the use of active and sometimes questionable liquids such as solvents in the finished drug product.
Currently there is only one drug approved for both acute and delayed onset CINV via serotonin 5-HT3 antagonists, Palonosetron. Serotonin 5-HT3 antagonists work by blocking the effects of a chemical called serotonin, which is produced in the brain and stomach. They prevent and relieve nausea and vomiting caused by chemotherapy. APF530 works by utilizing its delivery system and the 5-HT3 receptor antagonist, Granisetron, as its active ingredient. Granisetron was approved by the FDA for the treatment of acute onset CINV in 1994. The patent on it expired in 2007, so it is freely available for use in APF530.
An advantage of utilizing a previously-approved active ingredient is that the NDA can be submitted under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act in which the application can rely upon the FDA’s previous safety and efficacy profile for APF530’s active ingredient. For further information on how this may favor approval of APF530 please visit TapeBeat.Com for the full story.
Stephen Ramsey
Philip Runfeldt
Staff Writers
Mr. Ramsey is long APPA
By viewing this information you agree to the disclaimer found on TapeBeat.Com. The opinions expressed are that of the individual contributor(s). Neither the company releasing this information, nor the contributor(s) are associated with the company(s) mentioned or acting on their behalf. Neither TapeBeat.Com nor contributor(s) are certified financial advisor(s) or professional analysts. This is not a solicitation to trade in any security or a recommendation. Please do your own due diligence as, trading could result in loss of your principal.
Contact Information:
TapeBeat.Com
Philip Runfeldt
Tel: 888-209-2749
Email us
Recent HRTX News
- Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer • PR Newswire (US) • 09/03/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 08:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:05:13 PM
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • PR Newswire (US) • 08/06/2024 08:05:00 PM
- Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 • PR Newswire (US) • 07/30/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:54:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:44:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:32:57 PM
- Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System • PR Newswire (US) • 07/15/2024 12:00:00 PM
- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 06:21:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 01:34:07 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/31/2024 03:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:05:11 PM
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") • PR Newswire (US) • 05/29/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:05:13 PM
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • PR Newswire (US) • 04/24/2024 12:00:00 PM
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City • PR Newswire (US) • 04/11/2024 08:05:00 PM
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Biotech Finds Mid-Week Success Following Q4 Earnings Release • AllPennyStocks.com • 03/13/2024 08:25:00 PM
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Global Markets Await U.S. Inflation Report: Mixed Movements in Pre-Market Trading • IH Market News • 03/12/2024 11:22:57 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM